2021.02.27: MyBio Capital released the “2021 China Cross-border Transaction in Life Sciences-February.”

Under the dual driving forces of regulatory changes and capital pouring into the industry, China’s life sciences sector has become active in cross-border collaboration (licensing, investments, M&A) and achieved explosive growth in 2020. In 2021, MyBio Capital will continue to follow up global cross-border transaction dynamics and publish monthly report. Please click on the bottom of the article to download the February 2021 transaction highlights.

Attachment: 2021 China Cross-border Transaction in Life Sciences-February (click to download)